Literature DB >> 21040991

The metabolic response using 18F-fluorodeoxyglucose-positron emission tomography/computed tomography and the change in the carcinoembryonic antigen level for predicting response to pre-operative chemoradiotherapy in patients with rectal cancer.

Mee Sun Yoon1, Sung-Ja Ahn, Byung-Sik Nah, Woong-Ki Chung, Ju-Young Song, Jae-Uk Jeong, Taek-Keun Nam.   

Abstract

BACKGROUND AND
PURPOSE: To predict tumor regression in pre-operative chemoradiotherapy (CRT) using (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) and serum carcinoembryonic antigen (CEA) in patients with rectal cancer.
MATERIALS AND METHODS: The metabolic response of the tumor was assessed by determining the maximal standardized uptake value (SUV(max)), absolute difference (ΔSUV(max)), and SUV reduction ratio (SRR) on pre- and post-CRT PET/CT scans. The serum CEA, absolute difference (ΔCEA), and the CEA reduction ratio (CRR) were also determined. A receiver-operating characteristic (ROC) curve was generated.
RESULTS: Of all seventy two patients, mean pre- and post-CRT SUV(max) was 14.9 and 5.8, respectively. The mean pre- and post-CRT CEA level was 15.5 ng/ml and 5.4 ng/ml, respectively. Forty-three patients (59.8%) were classified as responders (Dworak's tumor regression grade 3-4) and 36 patients (50%) achieved tumor down-staging. ROC analysis showed that both post-CRT SUV(max) and SRR were predictive factors for responders (p=0.03 and p=0.02, respectively). A threshold of post-CRT SUV(max) was 5.4 and that of SRR was 53.1%. Pre-CRT SUV(max), ΔSUV(max), and all parameters in regard to CEA were not significant in ROC analysis.
CONCLUSIONS: The post-CRT SUV(max) and SRR are potential factors for predicting tumor response in pre-operative CRT. The patients with lower post-CRT SUV(max) and higher SRR could be expected to achieve maximum tumor regression after pre-operative CRT in this study. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21040991     DOI: 10.1016/j.radonc.2010.10.012

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy.

Authors:  Lucia Leccisotti; Maria Antonietta Gambacorta; Chiara de Waure; Antonella Stefanelli; Brunella Barbaro; Fabio Maria Vecchio; Claudio Coco; Roberto Persiani; Antonio Crucitti; Antonino Pio Tortorelli; Alessandro Giordano; Vincenzo Valentini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-17       Impact factor: 9.236

2.  Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future.

Authors:  Bengt Glimelius
Journal:  Ups J Med Sci       Date:  2012-05       Impact factor: 2.384

Review 3.  Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach.

Authors:  Jodi Rattner; Oliver F Bathe
Journal:  Metabolites       Date:  2017-11-16

4.  Early detection of treatment futility in patients with metastatic colorectal cancer.

Authors:  Jodi I Rattner; Karen A Kopciuk; Hans J Vogel; Patricia A Tang; Jeremy D Shapiro; Dongsheng Tu; Derek J Jonker; Lillian L Siu; Chris J O'Callaghan; Oliver F Bathe
Journal:  Oncotarget       Date:  2022-01-07

5.  Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Jing Yu; Ning Li; Xin Wang; Hua Ren; Weihu Wang; Shulian Wang; Yongwen Song; Yueping Liu; Yexiong Li; Xuantong Zhou; Aiping Luo; Zhihua Liu; Jing Jin
Journal:  Oncotarget       Date:  2016-09-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.